Table 4.
Studies included in the systematic review of prognosis
| Study | Demographics and follow-up | TID ratio (quant or qual), n(%) of pts with TID | Annualized cardiac outcomes |
|---|---|---|---|
| Abidov et al17
66.1 ± 12.8 years 50% men Ex and Pharm Dual |
Primary study cohort: 1560 pts with normal perfusion; Secondary cohort: 2037 pts with normal or near-normal perfusion: 2.3 ± 0.7 years |
1.21 (quant) n = 390 (25%) |
Outcome: cardiac death, MI, or coronary revascularization Normal perfusion (SSS = 0): (a) TID present: 2.4%·year−1; (b) No TID (i.e., lowest TID quartile): 0.6%·year−1 Normal/near-normal perfusion (SSS 0-3): (a) TID present: 2.2%·year−1; (b) Other 3 TID quartiles: 1.0%·year−1 |
| Petretta et al14
64 ± 8 years 67% men Ex and Pharm Tc 99m |
672 pts with DM 2+ years |
1.19 (quant) n = 97 (14%) |
Outcome: cardiac death or MI No ischemia + LVEF > 45%: (a) TID present: 4.9%·year−1 (b) No TID: 0.21%·year−1 Ischemia present + LVEF > 45%: (a) TID present: 5.4%·year−1 (b) No TID: 1.9%·year−1 Ischemia + LVEF ≤ 45%: (a) TID present: 7.2%·year−1 (b) No TID: 3.8%·year−1 |
| Doukky et al19
58 ± 12 years 52% men Ex and Pharm Tc 99m |
1236 pts with normal perfusion 27 ± 9 (clinical events) 37 ± 8 months (mortality) |
1.16 (Ex) 1.22 (Pharm) (quant) n = 76 (6%) |
Outcome: cardiac death or MI Overall: (a) TID present: 2.4%·year−1 (b) No TID: 0.4%·year−1 DM or CAD: (a) TID present: 5.9%·year−1 (b) No TID: 0.2%·year−1 |
| Uz zaman et al15
56 ± 9 years 67% men Ex and Pharm Tc 99m |
2689 pts in a single-center 18 ± 4 months |
1.22 (quant) n = 189 (7%) |
Outcome: fatal MI (a) TID + not revascularized: 3.3%·year−1 (b) TID + revascularized: 1.6%·year−1 (c) No TID: not reported Outcome: non-fatal MI (a) TID + not revascularized: 14.2%·year−1 (b) TID + revascularized: 3.3%·year−1 (c) No TID: not reported |
| Lette et al16
61 ± 10 years 55% men Pharm Tl 201 |
510 total pts; Prognostic cohort: 187 undergoing non-cardiac surgery 12 months |
1.15 (quant) n = 45 (9%) |
Outcome: cardiac death or MI (a) TID present: 58%·year−1 (b) Reversible defect: 19%·year−1 (c) Normal: 2%·year−1 |
| Lette et al35
62 years 57% men Pharm Tl 201 |
753 pts 16 months |
1.15 (quant) n = 41 (5%) |
Outcome: cardiac death or MI (a) TID present: 47.4%·year−1 (b) Reversible defect: 15.8%·year−1 (c) Normal: 2.0%·year−1 |
| Thomas et al36
65 ± 12 years 62% men Ex and Pharm Tc 99m and Dual |
1612 pts 24 ± 7 months |
Qualitative n = 371 (23%) |
Outcome: cardiac death or MI Technetium: (a) TID present: 6%·year−1 (b) No TID: 1.5%·year−1 Dual isotope: (a) TID present: 3.8%·year−1 (b) No TID: 0.5%·year−1 |
| De winter et al13
78 (IQR: 76-80) years 54% men Ex and Pharm Tc 99m |
294 pts aged ≥ 75 years old 26 months |
1.005 (quant) n = 147 |
Outcome: all-cause death (a) TID present: 9.7%·year−1 (b) No TID: 5.0%·year−1 |
TID, transient ischemic dilation; Ex, exercise stress; Pharm, pharmacologic stress; Dual, dual isotope study; MI, myocardial infarction; SSS, summed stress score; DM, diabetes; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; Pts, patients; IQR, interquartile range